Immuneering Corporation (IMRX) announced that it has appointed Harol Brakewood as its Chief Business Officer. Mr. Brakewood, who has more than 25 years of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development, new product planning, and commercial strategy. He joins Immuneering from Regeneron (REGN) Pharmaceuticals where he most recently served as Vice President, Business Unit Head for oncology, Covid-19, and new product planning.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMRX:
- Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- Immuneering presents preclinical data with lead program IMM-1-104
- Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley